Cronos Group Inc. (CRON)
USD 1.84
(-1.6%)
USD 1.84
(-1.6%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -81.37 Million USD | 29.86% |
| 2022 | -116.01 Million USD | -1809.83% |
| 2021 | 6.78 Million USD | 103.78% |
| 2020 | -179.34 Million USD | -47.63% |
| 2019 | -121.48 Million CAD | -813.77% |
| 2018 | -13.29 Million CAD | -693.09% |
| 2017 | -1.67 Million CAD | -36.83% |
| 2016 | -1.22 Million CAD | -326.74% |
| 2015 | 540.33 Thousand CAD | 117.56% |
| 2014 | -3.07 Million CAD | -396.63% |
| 2013 | -619.47 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -15.01 Million USD | -8.55% |
| 2024 Q1 | -13.82 Million USD | 25.93% |
| 2023 Q4 | -18.67 Million USD | -1074.29% |
| 2023 Q2 | -20.62 Million USD | 6.26% |
| 2023 Q3 | -1.59 Million USD | 92.29% |
| 2023 Q1 | -21.99 Million USD | 25.99% |
| 2023 FY | -81.37 Million USD | 29.86% |
| 2022 Q4 | -29.71 Million USD | 2.5% |
| 2022 Q3 | -30.48 Million USD | -13.75% |
| 2022 Q2 | -26.79 Million USD | 9.08% |
| 2022 FY | -116.01 Million USD | -1809.83% |
| 2022 Q1 | -29.47 Million USD | 81.88% |
| 2021 Q3 | -56.41 Million USD | 6.32% |
| 2021 Q4 | -162.63 Million USD | -188.29% |
| 2021 Q1 | -43.45 Million USD | 25.6% |
| 2021 FY | 6.78 Million USD | 103.78% |
| 2021 Q2 | -60.21 Million USD | -38.56% |
| 2020 Q1 | -45.06 Million USD | 29.45% |
| 2020 Q3 | -41.16 Million USD | -18.45% |
| 2020 Q4 | -58.41 Million USD | -41.88% |
| 2020 FY | -179.34 Million USD | -47.63% |
| 2020 Q2 | -34.75 Million USD | 22.87% |
| 2019 Q4 | -63.86 Million CAD | -56.11% |
| 2019 Q3 | -40.91 Million CAD | -164.01% |
| 2019 Q2 | -15.49 Million CAD | -3608.27% |
| 2019 Q1 | -417.91 Thousand CAD | 94.91% |
| 2019 FY | -121.48 Million CAD | -813.77% |
| 2018 Q2 | 372.56 Thousand CAD | 122.09% |
| 2018 Q1 | -1.68 Million CAD | -1119.75% |
| 2018 Q3 | -3.77 Million CAD | -1113.17% |
| 2018 FY | -13.29 Million CAD | -693.09% |
| 2018 Q4 | -8.21 Million CAD | -117.59% |
| 2017 Q2 | -2.46 Million CAD | -217.01% |
| 2017 FY | -1.67 Million CAD | -36.83% |
| 2017 Q4 | 165.38 Thousand CAD | 632.73% |
| 2017 Q3 | -31.04 Thousand CAD | 98.74% |
| 2017 Q1 | -776.01 Thousand CAD | -155.94% |
| 2016 Q1 | -373.55 Thousand CAD | -115.91% |
| 2016 Q3 | -266.05 Thousand CAD | 85.71% |
| 2016 Q2 | -1.86 Million CAD | -398.33% |
| 2016 Q4 | 1.38 Million CAD | 621.43% |
| 2016 FY | -1.22 Million CAD | -326.74% |
| 2015 Q2 | -556.79 Thousand CAD | 26.5% |
| 2015 Q4 | 2.34 Million CAD | 575.95% |
| 2015 FY | 540.33 Thousand CAD | 117.56% |
| 2015 Q3 | -493.33 Thousand CAD | 11.4% |
| 2015 Q1 | -757.54 Thousand CAD | 0.0% |
| 2014 Q3 | -76.68 Thousand CAD | -647.61% |
| 2014 Q2 | -10.25 Thousand CAD | 0.0% |
| 2014 FY | -3.07 Million CAD | -396.63% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 FY | -619.47 Thousand CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 273.246% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | -438.839% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 148.739% |
| Cosmos Health Inc. | -21.83 Million USD | -272.748% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -305.861% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 47.69% |
| Incannex Healthcare Limited | -30.04 Million USD | -170.881% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -107.84% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 972.098% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | -1617.968% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -1600.53% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | -1600.53% |
| SCYNEXIS, Inc. | 72.66 Million USD | 211.981% |
| Safety Shot Inc | -12.18 Million USD | -567.88% |
| Theratechnologies Inc. | -10.62 Million USD | -665.743% |
| Alpha Teknova, Inc. | -35.56 Million USD | -128.821% |
| Universe Pharmaceuticals INC | -3.52 Million USD | -2207.362% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 192.815% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | -1631.024% |
| Dynavax Technologies Corporation | -37.02 Million USD | -119.767% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 138.929% |
| Radius Health, Inc. | -3.92 Million USD | -1973.26% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | -3135.326% |
| Alvotech | -354.86 Million USD | 77.068% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 48.943% |
| SIGA Technologies, Inc. | 83.62 Million USD | 197.314% |
| Shineco, Inc. | -17.06 Million USD | -376.832% |
| Silver Spike Investment Corp. | 7.34 Million USD | 1208.641% |
| Journey Medical Corporation | -2.07 Million USD | -3825.492% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | -497.586% |
| Embecta Corp. | 221.5 Million USD | 136.738% |
| Harrow Health, Inc. | 580 Thousand USD | 14130.251% |
| Procaps Group, S.A. | 38.97 Million USD | 308.8% |
| Biofrontera Inc. | -22.67 Million USD | -258.846% |
| DURECT Corporation | -36.88 Million USD | -120.625% |
| PainReform Ltd. | -9.58 Million USD | -749.076% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -1444.419% |
| OptiNose, Inc. | -22.74 Million USD | -257.726% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 744.201% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 749.704% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | -1210.221% |
| ProPhase Labs, Inc. | -21.61 Million USD | -276.512% |
| Phibro Animal Health Corporation | 53.31 Million USD | 252.631% |
| Procaps Group S.A. | 52.32 Million USD | 255.522% |
| TherapeuticsMD, Inc. | -8.52 Million USD | -854.775% |
| Viatris Inc. | 766.2 Million USD | 110.621% |
| Rockwell Medical, Inc. | -6.67 Million USD | -1120.022% |
| Aytu BioPharma, Inc. | -5.25 Million USD | -1448.829% |
| Tilray Brands, Inc. | -174.74 Million USD | 53.432% |
| PetIQ, Inc. | 60.01 Million USD | 235.592% |
| Talphera, Inc. | -16.88 Million USD | -381.825% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 132.433% |
| Alimera Sciences, Inc. | -1.47 Million USD | -5431.982% |
| Assertio Holdings, Inc. | -243.53 Million USD | 66.586% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | -1281.029% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 40.968% |
| Hempacco Co., Inc. | -8.81 Million USD | -823.433% |
| Alvotech | -354.86 Million USD | 77.068% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 122.317% |
| Kamada Ltd. | 10.06 Million USD | 908.58% |
| Currenc Group, Inc. | -6.64 Million USD | -1124.467% |
| Indivior PLC | -4 Million USD | -1934.386% |
| Evoke Pharma, Inc. | -7.43 Million USD | -995.097% |
| Flora Growth Corp. | -50.35 Million USD | -61.607% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -305.861% |
| Evolus, Inc. | -49.23 Million USD | -65.286% |
| HUTCHMED (China) Limited | 18.37 Million USD | 542.86% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 141.31% |
| Akanda Corp. | -10.05 Million USD | -709.595% |